根據最新的財務報表(Form-10K),ProUroCare Medical Inc 的總資產為 $0,淨損失為 $-2
PUMD 的關鍵財務比率是什麼?
ProUroCare Medical Inc 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
ProUroCare Medical Inc 的收入按細分市場或地理位置如何劃分?
ProUroCare Medical Inc 最大收入來源為 Pharmaceutical and Specialty Solutions,在最近的收益報告中收入為 204,644,000,000。就地區而言,United States 是 ProUroCare Medical Inc 的主要市場,收入為 220,993,000,000。
ProUroCare Medical Inc 是否盈利?
無,根據最新的財務報表,ProUroCare Medical Inc 的淨損失為 $-2
ProUroCare Medical Inc 有負債嗎?
是的,ProUroCare Medical Inc 的負債為 4
ProUroCare Medical Inc 的流通股有多少?
ProUroCare Medical Inc 的總流通股為 18.27
關鍵數據
前收市價
$0.0001
開盤價
$0.0002
當日範圍
$0.0001 - $0.0002
52週區間
$0.0001 - $0.0002
交易量
26.1K
平均成交量
362
股息收益率
--
每股盈餘 (TTM)
-0.14
市值
$1.8K
什麼是 PUMD?
ProUroCare Medical, Inc. engages in the development of products for the detection and characterization of male prostate disease. The company is headquartered in Eden Prairie, Minnesota and currently employs 2 full-time employees. The company went IPO on 2002-05-28. The firm is focused on its product, a prostate mechanical imaging device called the ProUroScan System. The ProUroScan is an advanced medical imaging system that uses an array of sensors mounted on a rectal probe, a central processing unit and software and image construction algorithms to provide a real time color image of abnormalities in the prostate. The ProUroScan System probe is specially designed for the rectal anatomy to minimize patient discomfort. In addition, it provides mechanical or elasticity imaging, which refers to a non-invasive analysis of tissue movement and displacement. The ProUroScan technique works by computing how tissue moves in response to pressure, thus evaluating its softness or stiffness. Its product also provides two-and three-dimensional prostate images.